Preventing recurrent tuberculosis in high HIV-prevalent areas in sub-Saharan Africa: What are the options for tuberculosis control programmes?

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 7, 2003, Pages 616-622

  Harries, Anthony D ^a,d   Chimzizi, R B ^a   Nyirenda, T E ^a,b   Van Gorkom, J ^c   Salaniponi, F M ^a  

^a National Tuberculosis Programme   (Malawi)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^d British High Commission   (Malawi)

Author keywords

Antiretroviral therapy; HIV; Isoniazid; Recurrent TB

Indexed keywords

ANTIRETROVIRUS AGENT; ETHAMBUTOL; ISONIAZID; RIFAMPICIN;

AFRICA SOUTH OF THE SAHARA; ARTICLE; BACTERIAL TRANSMISSION; CLINICAL TRIAL; EPIDEMIC; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RISK; LUNG TUBERCULOSIS; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REGISTRATION; SERODIAGNOSIS; SPUTUM SMEAR;

AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEALTH POLICY; HIV INFECTIONS; HUMANS; ISONIAZID; RECURRENCE; TUBERCULOSIS;

EID: 0037820433     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Perriens J H, Colebunders R L, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with 'standard' chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991; 144: 750-755.
2. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1 infected patients in Kenya. Lancet 1993; 342: 332-337.
3. Elliott A M, Halwiindi B, Hayes R J, et al. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia. J Trop Med Hyg 1995; 98: 9-21.
4. Kelly P M, Cumming R G, Kaldor J M. HIV and tuberculosis in rural sub-Saharan Africa: a cohort study with two year follow-up. Trans Roy Soc Trop Med Hyg 1999; 93: 287-293.
5. Mallory K F, Churchyard G J, Kleinschmidt I, De Cock K M, Corbett E L. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2000; 4: 455-462.
6. Banda H, Kang'ombe C, Harries A D, et al. Mortality rates and recurrent rates of tuberculosis in patients with smear-negative pulmonary tuberculosis and tuberculous pleural effusion who have completed treatment. Int J Tuberc Lung Dis 2000; 4: 968-974.
7. Sonnenberg P, Murray J, Glynn J R, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693.
8. Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995; 9: 1185-1191.
9. van den Broek J, Mfinanga S, Moshiro C, O'Brien R, Mugomela A, Lefi M. Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. Int J Tuberc Lung Dis 1998; 2: 547-552.
10. World Health Organization. Treatment of tuberculosis guidelines for national programmes. 2nd ed. WHO/TB/97.220. Geneva: WHO, 1997.
11. Kwanjana J H, Harries A D, Gausi F, Nyangulu D S, Salaniponi F M L. TB-HIV seroprevalence in patients with tuberculosis in Malawi. Malawi Med J 2001; 13: 7-10.
12. Harries A D, Hargreaves N J, Kwanjana J H, Salaniponi F M L. Relapse and recurrent tuberculosis in the context of a National Tuberculosis Control Programme. Trans Roy Soc Trop Med Hyg 2000; 94: 247-249.
13. Harries A D, Salaniponi F M L. Recurrent tuberculosis in Malawi: improved diagnosis and management following operational research. Trans Roy Soc Trop Med Hyg 2001; 95: 503-504.
14. De Cock K M, Chaisson R E. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999; 3: 457-465.
15. Johnson J L, Okwera A, Vjecha M J, et al. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 1997; 1: 446-453.
16. Malkin J E, Prazuck T, Simonnet F, et al. Tuberculosis and human immunodeficiency virus infection in West Burkina Faso: clinical presentation and clinical evolution. Int J Tuberc Lung Dis 1997; 1: 68-73.
17. Perriens J H, St. Louis M E, Mukadi Y B, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332: 779-784.
18. van Gorkom J, van Cleeff M, Becx-Bleumink M, Veen J. Short-course instead of long-course chemotherapy for smear-negative patients in sub-Saharan Africa. Int J Tuberc Lung Dis 2001; 5: 4-11.
19. Rieder H L, Arnadottir T, Trébucq A, Enarson D A. Tuberculosis treatment: dangerous regimens? Int J Tuberc Lung Dis 2001; 5: 1-3.
20. Fitzgerald D W, Desvarieux M, Severe P, Joseph P, Johnson W D Jr, Pape J W. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356: 1470-1474.
21. World Health Organization. Preventive therapy against tuberculosis in people living with HIV. Policy statement. Weekly Epidemiological Record 1999; 46: 385-398.
22. Girard P-M. Discontinuing Pneumocystis carinii prophylaxis. N Engl J Med 2001; 344: 222-223.
23. Jones J L, Hanson D L, Dworkin M S, De Cock K M, and The Adult/Adolescent Spectrum of HIV Disease Group. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis 2000; 4: 1026-1031.
24. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14: 1985-1991.
25. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064.
26. Kapp C. Global Fund faces uncertain future as cash runs low. Lancet 2002; 360: 1225.
27. Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002; 359: 1635-1642.
28. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a Public Health Approach. Geneva: WHO HIV/AIDS Department, Family and Community Health Cluster, 2002.
29. Mukadi Y D, Maher D, Harries A D. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001; 15: 143-152.
30. World Health Organization. Strategic framework to decrease the burden of TB/HIV. WHO/CDS/TB/2002.296. Geneva: WHO, 2002.